Remember when we used to talk about other stuff?
Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And will there ever be an Apple of pharma? We cover all that and more this week on "The Readout LOUD," STAT's biotech podcast. In the wake of a massively important clinical trial of Novo Nordisk's obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don't know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company. Listen Now Subscribe to the podcast to never miss an episode Visit the archive to see past episodes |
|
| STAT, 1 Exchange Place, Boston, MA | ©2023, All Rights Reserved. | |
|
No comments